Cancer patients get chance to keep Life-Extending drugs
NCT ID NCT07172919
Summary
This study allows people with advanced solid tumors and a specific KRAS gene mutation to continue taking an experimental drug combination if they are already benefiting from it in a previous Amgen trial. The main goal is to check the long-term safety and side effects of continuing these treatments. It is for patients whose original study has ended but who are still doing well on the therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Hospital Organization Hokkaido Cancer Center
RECRUITINGSapporo, Hokkaido, 003-0804, Japan
-
Taichung Veterans General Hospital
RECRUITINGTaichung, 40705, Taiwan
-
Universitaetsspital Basel
RECRUITINGBasel, 4031, Switzerland
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.